-The Hindu The State population stands at a little over three crore, but average consumption of drugs is three times the national average In Kerala, where people have a marked preference for branded drugs, where the most expensive brand is considered the best, and only those brands pushed by doctors sell, the new Drug (Prices Control) Order, which is expected to cut prices by 20-25 per cent, may not have much of...
More »SEARCH RESULT
Paying the price-Ramya Kannan
-The Hindu The much-awaited Drug (Prices Control) Order 2013 has disappointed millions of patients, as it lacks a fair formula to fix the price ceiling and leaves important drug classes out of regulation. The result: High out-of-pocket spending on medicines will continue As far as intentions go, the Drug (Prices Control) Order 2013 is aimed at making critical drugs affordable and available to the public, while preserving a rationale for manufacture by...
More »Health tips for caller tunes
-The Telegraph New Delhi: The World Health Organisation wants India's public to give up Bollywood songs as caller tunes on their mobile phones and replace them with short health messages from superstars of India's entertainment industry. The global health agency today launched what is being dubbed as the world's first attempt to promote health campaigns via caller tunes, drawing on the voices of 10 personalities from Bollywood and other entertainment sectors. Amitabh Bachchan's...
More »UN report cites advertising ban as powerful tool in reducing tobacco use
-The United Nations One in three people is now covered by at least one life-saving measure to limit tobacco use, according to a United Nations report which highlights the progress over the past five years of reducing potential smokers through advertising bans and awareness campaigns. According to the report on the Global Tobacco Epidemic 2013, the number of people covered by bans on tobacco advertising, promotion and sponsorship increased by almost 400...
More »Monsanto’s climate-resilient crop patent claims rejected -Sanjay Vijayakumar
-The Economic Times CHENNAI: India's patent appeals board has denied Monsanto a patent for a genetically-engineered method of increasing climate resilience in plants. The decision is significant not only for Monsanto's loss of possible exclusivity in an increasingly important segment but also for the interpretation of India's home-grown clauses in patent law - these are unpopular with global companies - for the first time in the case of plants. The Intellectual Property...
More »